MedTrace Logo

APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's Disease

NCT04994847 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-07-20

No results posted yet for this study

Summary

The purpose of this study is to track changes in the brain related to Alzheimer's disease. The results from this study will be used to develop new approaches to prevent or delay the onset of memory and thinking problems associated with Alzheimer's.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Amyloid and Tau PET

NAV4694 and MK6240 PET scans completed every two years

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Banner Health

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04994847 on ClinicalTrials.gov